Tislelizumab combined with nab-paclitaxel, adriamycin and cyclophosphamide chemotherapy in neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study

被引：0
|
作者：
Zhang, G. [1 ]
He, Y. [1 ]
Luo, D. [1 ]
Zhang, X. [1 ]
Gao, B. [1 ]
Jiang, Y. [1 ]
Zhao, J. [1 ]
Guo, L. [1 ]
Xu, Y. [1 ]
机构：
[1] Army Specialty Med Ctr PLA, Dept Breast & Thyroid Surg, Chongqing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
26TiP
引用
收藏
页码：S1414 / S1414
页数：1
相关论文
共 50 条
  • [1] Nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide in neoadjuvant chemotherapy for triple-negative breast cancer: an open-label, single-arm phase II study
    Liu, Yin
    Fan, Lei
    Shao, Zhi-Ming
    Wang, Zhong-Hua
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
    Luo, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost.
    Fasching, Peter A.
    Hartkopf, Andreas
    Kolberg, Hans-Christian
    Haeberle, Lothar
    Wetzig, Sarah
    Mau, Christine
    Engler, Tobias
    Ruebner, Matthias
    Huebner, Hanna
    Theuser, Anna-Katharin
    Hummel, Nadine
    Uhrig, Sabrina
    Beckmann, Matthias W.
    Hein, Alexander
    Untch, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study
    He, Min
    Hao, Shuang
    Ma, LinXiaoxi
    Xiu, BingQiu
    Yang, BenLong
    Wang, ZeHao
    Xue, JingYan
    Chi, YaYun
    Xiong, Min
    Chen, Jiajian
    Huang, XiaoYan
    Liu, XiYu
    Wu, SongYang
    Xiao, Qin
    Huang, Yan
    Shui, RuoHong
    Cao, AYong
    Li, JunJie
    Di, GenHong
    Yang, WenTao
    Hu, Xin
    Liu, GuangYu
    Yu, KeDa
    Jiang, YiZhou
    Wang, ZhongHua
    Shao, ZhiMing
    Wu, Jiong
    ECLINICALMEDICINE, 2024, 74
  • [5] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A singlearm, open-label, phase II study
    Wang, C.
    Liu, Z.
    Chen, X.
    Qiao, J.
    Li, L.
    Lu, Z.
    Sun, X.
    ANNALS OF ONCOLOGY, 2021, 32 : S436 - S436
  • [6] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
    Wang, Chengzheng
    Liu, Zhenzhen
    Chen, Xiuchun
    Qiao, Jianghua
    Lu, Zhenduo
    Li, Lianfang
    Sun, Xianfu
    Zhang, Chongjian
    Yue, Xiayu
    Xia, Qingxin
    Zhang, He
    Yan, Min
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [7] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
    Chengzheng Wang
    Zhenzhen Liu
    Xiuchun Chen
    Jianghua Qiao
    Zhenduo Lu
    Lianfang Li
    Xianfu Sun
    Chongjian Zhang
    Xiayu Yue
    Qingxin Xia
    He Zhang
    Min Yan
    Nature Communications, 14 (1)
  • [8] Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
    Chen, Li
    Jiang, Yi-Zhou
    Wu, Song-Yang
    Wu, Jiong
    Di, Gen -Hong
    Liu, Guang-Yu
    Yu, Ke-Da
    Fan, Lei
    Li, Jun-Jie
    Hou, Yi-Feng
    Hu, Zhen
    Chen, Can-Ming
    Huang, Xiao-Yan
    Cao, A-Yong
    Hu, Xin
    Zhao, Shen
    Ma, Xiao-Yan
    Xu, Ying
    Sun, Xiang-Jie
    Chai, Wen -Jun
    Guo, Xiaomao
    Chen, Xizi
    Xu, Yanhui
    Zhu, Xiao-Yu
    Zou, Jian-Jun
    Yang, Wen-Tao
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2807 - 2817
  • [9] Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
    Liu, Yin
    Fan, Lei
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    ONCOLOGIST, 2023, 28 (01): : 86 - +
  • [10] A phase II trial of neoadjuvant apatinib combined with nab-paclitaxel and carboplatin in triple-negative breast cancer
    Zeng, Tianyu
    Wang, Jue
    Li, Wei
    Sun, Chunxiao
    Yang, Fan
    Liang, Yan
    Fu, Ziyi
    Zha, Xiaoming
    Yin, Yongmei
    ANNALS OF ONCOLOGY, 2022, 33 : S492 - S492
12345